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The Axl receptor tyrosine kinase (RTK) has been established as a strong candidate for targeted therapy of cancer.
However, the benefits of targeted therapies are limited due to acquired resistance and activation of alternative
RTKs. Therefore, we asked if cancer cells are able to overcome targeted Axl therapies. Here, we demonstrate that
inhibition of Axl by short interfering RNA or the tyrosine kinase inhibitor (TKI) BMS777607 induces the expression
of human epidermal growth factor receptor 3 (HER3) and the neuregulin 1(NRG1)–dependent phosphorylation of
HER3 in MDA-MB231 and Ovcar8 cells. Moreover, analysis of 20 Axl-expressing cancer cell lines of different tissue
origin indicates a low basal phosphorylation of RAC-α serine/threonine-protein kinase (AKT) as a general
requirement for HER3 activation on Axl inhibition. Consequently, phosphorylation of AKT arises as an independent
biomarker for Axl treatment. Additionally, we introduce phosphorylation of HER3 as an independent
pharmacodynamic biomarker for monitoring of anti-Axl therapy response. Inhibition of cell viability by
BMS777607 could be rescued by NRG1-dependent activation of HER3, suggesting an escape mechanism by
tumor microenvironment. The Axl-TKI MPCD84111 simultaneously blocked Axl and HER2/3 signaling and thereby
prohibited HER3 feedback activation. Furthermore, dual inhibition of Axl and HER2/3 using BMS777607 and
lapatinib led to a significant inhibition of cell viability in Axl-expressing MDA-MB231 and Ovcar8 cells. Therefore,
we conclude that, in patient cohorts with expression of Axl and low basal activity of AKT, a combined inhibition of
Axl and HER2/3 kinase would be beneficial to overcome acquired resistance to Axl-targeted therapies.
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Axl is a member of the unique Tyro3, Axl, MerTK family of receptor
tyrosine kinases (RTKs). Axl was first identified as an oncogene in
patients with chronic myelogenous leukemia [1] and was shown to
have transforming activity when transfected into NIH/3T3 cells [2].
Axl activation occurs by binding of growth arrest–specific gene 6, its
only validated ligand [3,4]. Axl signaling stimulates phosphatidyli-
nositide 3-kinase/RAC-α serine/threonine-protein kinase (PI3K/
AKT), extracellular signal-regulated kinase (ERK) and p38 mito-
gen-activated protein kinase cascades, the nuclear factor-kappa B
(NF-κB) pathway, and signal transducer and activator of transcription
signaling [5]. Consequently, Axl signaling modulates biologicprocesses, including invasion, angiogenesis, resistance to chemother-
apeutics and targeted drugs, survival, and proliferation, which
represent characteristics associated with malignancies [6].
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myelogenous leukemia, Axl expression was observed in more than 20
human tumor entities and is associated in most cases with tumor
progression [7]. High expression of Axl in primary lung and
pancreatic adenocarcinomas correlates with lymph node status and
disseminated disease [8–10]. In glioblastoma multiforme, Axl
expression is associated with an actively migrating cell population
that predicts aggressive behavior [11]. Importantly, primary ovary
carcinoma [12], lung carcinoma [13], breast carcinoma [14], renal cell
carcinoma [15], glioblastoma multiforme [16], or acute myeloid
leukemia [17] with high Axl expression levels correlate with shorter
progression-free and overall survival. These studies suggest that
expression of Axl confers aggressive tumor behavior, leading to tumor
dissemination and mortality from metastasis.
Axl up-regulation has also been described in cisplatin-resistant
ovarian cancer [18], doxorubicin-resistant acute myeloid leukemia
[19], lapatinib-resistant breast cancer [20], imatinib-resistant
gastrointestinal stromal tumors [21], and imatinib-resistant chronic
myeloid leukemia [22]. Lately, Axl activation has been reported as a
cause of resistance to epidermal growth factor receptor (EGFR)-
targeted therapy in non–small cell lung cancers [23,13]. These
studies support the well-known fact that the benefits of single-
targeted therapies are limited due to resistance formation by
activation of alternative RTKs. Hence, we asked if targeted Axl
therapies would result in the activation of other RTKs to
circumvent Axl inhibition. To answer this question, we blocked
Axl phosphorylation in MDA-MB231 cells overexpressing Axl by
short interfering RNA-mediated knockdown or by treatment with
three selective Axl tyrosine kinase inhibitors (TKIs), namely,
BMS777607, R428, and MPCD84111. BMS777607 was recently
published as a Met inhibitor but also targets Axl RTK very
potently at low nanomolar concentrations [24]. R428 is a selective
TKI published by Holland et al. entering clinical phase I studies in
the near future [25]. MPCD84111 was recently patented as a new
Axl TKI by our group.
In contrast to MPCD84111, BMS777607 and R428 induce a
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3/
human epidermal growth factor receptor 3 (ERBB3/HER3)-
activating feedback loop mechanism depending on inhibition of
PI3K/AKT signaling. Inhibition of cell viability by BMS777607 was
rescued with the HER2/3 ligand neuregulin 1 (NRG1), suggesting a
possible mechanism of tumor cell escape. MPCD84111 simulta-
neously blocked Axl and HER2/3 signaling, thereby prohibiting this
HER3 feedback loop. Importantly, blocking of Axl by BMS777607
and HER2/3 by lapatinib led to synergistic or at least additive
inhibition of cell viability of MDA-MB231 and Ovcar8 cells. This
provides a strong rationale for combined inhibition of Axl and
HER2/3 kinase signaling in patients with Axl-amplified tumors.
Materials and Methods
Cell Culture Techniques
Cell lines were grown in a humidified, 5% CO2 incubator at 37°C.
The human cancer cell lines MDA-MB231, A549, C4-I, A172,
U373, Panc-1, SF126, U118, and NIH/3T3-Axl fibroblasts were
maintained in Dulbecco's modified Eagle medium supplemented
with 1% sodium pyruvate and 10% FBS. Hs578T, NCI-H1975,
NCI-H1299, NCI-H292, Ovcar8, BxPC3, BT549, MDA-MB436,
and MDA-MB468 were routinely passaged in Roswell ParkMemorial Institute 1640 medium supplemented with 1% gluta-
mine and 10% FBS. MDA-MB231-D3H2LN and Capan-2 were
cultivated in minimum essential media supplemented with 1%
sodium pyruvate, 1% glutamine, 1% nonessential amino acids, and
10% FBS. McCoy 5A medium (modified) supplemented with 10%
FBS was used for SKOV-3 cells. Cell culture media were purchased
from Gibco (Invitrogen, Bleiswijk, The Netherlands), and
supplements were ordered from GE Healthcare (Wien, Austria).
Three dimensional (3D) Spheroid Culture
BD Matrigel Basement Membrane Matrix (BD Biosciences,
Bedford, MA, No. 354234) was diluted at a concentration of 3
mg/ml in cell line–corresponding serum-free medium. Eighty
microliters of precooled Matrigel was pipetted into the wells of
precooled 96-well plates. The Matrigel polymerized at least 16 hours
at 37°C. Cells (7000 per well) in 120 μl of medium were seeded on
top of the solid Matrigel and formed spheroidlike structures within 72
hours. Inhibitor treatments were initiated at the moment of cell
seeding into Matrigel.
RNA Interference
Transfection of 21-nucleotide siRNA duplexes (Axl No. s1845,
Met No. s8701, HER2 No. 540, HER3 No. s4780, and Ambion
Control No. 1; Ambion/Invitrogen, Darmstadt, Germany and
EGFR, No. J-003114-13; Thermo Scientific Dharmacon, Schwerte,
Germany) was carried out using Lipofectamine RNAiMAX (Invitro-
gen, Darmstadt, Germany) and OPTI-MEM media (Gibco/Invitro-
gen, Bleiswijk, The Netherlands). After 6 hours, medium was
changed to normal medium containing 10% FBS. Cells were used for
subsequent experiments after additional 48 hours of incubation.
Cell Viability
We measured cell viability using a luciferase-coupled ATP
quantitation assay (CellTiter-Glo; Promega, Mannheim, Germany).
Cells were incubated for 72 hours, and the CellTiter-Glo reagent was
added according to the manufacturer's instructions. The lumines-
cence signal was recorded using a microplate luminometer, LB 96V
(Berthold Technologies, Bad Wildbad, Germany). The experiments
were performed at least in triplicate.
Human Phospho-RTK Array
Human Phospho-RTK array (R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany, No. ARY001) was used according to the
manufacturer's instructions. Briefly, cells were lysed on ice in lysis buffer
[50mMHepes (pH 7.5), 150mMNaCl, 1 mMEGTA, 10% glycerol,
1% Triton X-100, 100 mM NaF, 10 mM Na4P2O7
*10 H2O, 1 mM
Na3VO4, 1 mM PMSF, and 10 mg/ml aprotinin, all purchased from
Sigma-Aldrich, Steinheim, Germany] for 15 minutes. Five hundred
micrograms of lysates was incubated with blocked array membranes
overnight. Detection was performed using enhanced chemilumines-
cence (Western Lightning; PerkinElmer, Rodgau, Germany).
Western Blot Analysis
Cells were lysed in lysis buffer for 15 minutes. Equal amounts of
protein were resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Proteins were transferred to nitrocellulose mem-
branes (Schleicher and Schuell BioScience GmbH, Dassel, Germany),
blocked for 1 hour, and incubated at 4°C overnight with the
corresponding primary antibody. pHER3 Y1289 (No. 4791),
pHER2 Y1248 (No. 2247), EGFR (No. 2232), and pAKT S473
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Technology (Cell Signaling Technology/New England Biolabs
GmbH, Frankfurt am Main, Germany). The anti-HER2 (No. 06-
562) and anti-HER3 (No. 05-390; Millipore, Schwalbach, Germa-
ny), anti-Met (No. sc-161; Santa Cruz Biotechnology, Heidelberg,
Germany), and the anti-Tubulin (No. T9026) antibody was
purchased from Sigma-Aldrich. For phospho-tyrosine (p-Tyr)
detection, the homemade anti–p-Tyr clone 4G10 was used.
Membranes were blocked and incubated with an HRP-conjugated
anti-rabbit or anti-mouse secondary antibody (Jackson Immuno
Research Europe Ltd., Suffolk, UK) for 1 hour at room temperature.
Detection was performed using enhanced chemiluminescence
(Western Lightning; PerkinElmer, Rodgau, Germany). Densitomet-
ric analysis was conducted using ImageJ software from the National
Institutes of Health (Bethesda, MD). The changes of intensity
reported in the figures were obtained as a ratio between the DMSO
control or siRNA control band intensity and the band intensity of
interest after indicated treatment. All bands were normalized to
Tubulin as loading control.
Immunoprecipitation
Respective antibodies were precoupled to 40 μl of A-Sepharose
beads (GE Healthcare, Munich, Germany, No. 17-5280-04) in lysis
buffer for 1 hour and washed three times with lysis buffer. Lysates and
precoupled antibody-beads were incubated at 4°C for 16 hours, and
precipitates were washed three times with 1 ml of lysis buffer,
suspended in Laemmli buffer, boiled for 10 minutes, and analyzed by
Western blot. Antibodies used for immunoprecipitation (IP) were
HER3 (No. 05-390) and HER2 (No. 06-562) purchased from
Millipore or HER2 homemade antibody clone 13D1B1.
Enzyme-Linked Immunosorbent Assay (ELISA)
Phospho-Axl ELISA. Axl phosphorylation was determined using
phospho-tyrosine Axl ELISA (p-Tyr–Axl ELISA). Onto six-well
plates, 75,000 NIH/3T3-Axl cells were seeded, starved for 24 hours,
and then treated with serially diluted inhibitor concentrations for 1
hour. Cells were lysed on ice in 400 μl of lysis buffer for 15 minutes.
Ninety-six–well Nunc MicroWell plates (Fisher Scientific GmbH,
Schwerte, Germany) were coated overnight with 2 μg/ml homemade
anti-Axl capture antibody (homemade clone 259/2, IgG1 isotype) in
phosphate-buffered saline (PBS) (100 μl per well). Subsequently, 96-
well plates were blocked with PBS/0.05% Tween 20 (Sigma-Aldrich,
Steinheim, Germany) + 10% FBS for 4 hours at 37°C. Plates were
washed five times with PBS/0.05% Tween 20, and 95 μl of lysate was
transferred per well for incubation overnight at 4°C. Plates were
washed five times with PBS/0.05% Tween 20. For detection of
phosphorylated tyrosine, we used the biotinylated homemade anti–p-
Tyr clone 4G10 antibody (0.5 μg/ml) in PBS/0.05% Tween 20 +
10% FBS (100 μl per well) and incubated the 96-well plate for 2
hours at room temperature. The 4G10 antibody was biotinylated
with Sulfo-NHS-Biotin according to the supplier’s protocol (Pierce,
Rockford, IL) and purified by Micro Bio-Spin 6 chromatography
columns (Bio-Rad Laboratories, Inc, Hercules, CA) using PBS as
diluent. Plates were washed five times with PBS/0.05% Tween 20.
Alkaline phosphatase–conjugated streptavidin SA110 (Millipore,
Schwalbach, Germany) (1:4000) was used in PBS/0.05% Tween
20 + 10% FBS (100 μl per well) and incubated for 30 minutes at
room temperature. Plates were washed five times with PBS/0.05%
Tween 20. For fluorometric detection of alkaline phosphatase,AttoPhos substrate set (Roche Diagnostics GmbH, Mannheim,
Germany) was used (100 μl per well). The fluorometric signal was
quantified after 90 minutes at a wavelength of 430/560 nm using a
TECAN Ultra Evolution plate reader (Tecan Deutschland GmbH,
Crailsheim, Germany). The Patent No. WO2011045084A owned by
the Max Planck Society contains a detailed description of the p-Tyr–
Axl ELISA and the generation of Axl-expressing NIH/3T3-Axl cells
used for this ELISA.
Neuregulin 1–enzyme-linked immunosorbent assay. We used a
specific human NRG1-ELISA (R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany, No. DY377) to quantify protein amounts
according to the manufacturer's protocol with the following
modifications: After the incubation with a biotinylated detection
antibody specific for NRG1 (1:180), we used an alkaline
phosphatase–conjugated streptavidin SA110 (Millipore, Schwal-
bach, Germany) (1:4000) at room temperature. For fluorometric
detection of alkaline phosphatase, AttoPhos substrate set (Roche
Diagnostics GmbH, Mannheim, Germany) was used (100 μl per
well). The fluorometric signal was quantified after 90 minutes at a
wavelength of 430/560 nm using a TECAN Ultra Evolution plate
reader (Tecan Deutschland GmbH, Crailsheim, Germany). All
antibodies were diluted in PBS/0.05% Tween 20 + 1% BSA (100 μl
per well). The plates were washed five times with PBS/0.05%
Tween 20.
Phospho-AKT S473 ELISA. The Pan AKT-specific ELISA kit
(R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany, No.
DYC887B-5) was used for quantification of phospho-AKT S473
according to the manufacturer's protocol with the following
modifications: After the incubation with a biotinylated phospho-
AKT (S473) panspecific detection antibody (1:180), we used an
alkaline phosphatase–conjugated streptavidin SA110 (Millipore,
Schwalbach, Germany) (1:4000) at room temperature. For fluoro-
metric detection of alkaline phosphatase, AttoPhos substrate set
(Roche Diagnostics GmbH, Mannheim, Germany) was used (100 μl
per well). The fluorometric signal was quantified after 90 minutes
at a wavelength of 430/560 nm using a TECAN Ultra Evolution
plate reader (Tecan Deutschland GmbH, Crailsheim, Germany).
All antibodies were diluted in PBS/0.05% Tween 20 + 1% BSA
(100 μl per well). The plates were washed five times with PBS/0.05%
Tween 20.
Quantitative Polymerase Chain Reaction
MDA-MB231 cells were treated with 10 μM BMS777607 or
DMSO for the indicated periods of time. RNA preparation [RNeasy
Mini Kit (50); QIAshredder; Qiagen, Hilden, Germany] and first-
strand cDNA synthesis (First Strand cDNA Synthesis Kit; Fermentas/
Fisher Scientific GmbH) were performed according to the manu-
facturer's protocol. For cDNA synthesis, 1 μg of total RNA and
200 ng of random hexamer primer were used. The Gene database
search on National Center for Biotechnology Information platform
(Bethesda, MD) revealed 17 different NRG1 isoforms inHomo sapiens
(Gene ID: 3084): No. 1, NM_001159995.1; No. 2,
NM_001159996.1; No. 3, NM_001159999.1; No. 4,
NM_001160001.1; No. 5, NM_001160002.1; No. 6,
NM_001160004.1; No. 7, NM_001160005.1; No. 8,
NM_001160007.1; No. 9, NM_001160008.1; No. 10,
NM_004495.3; No. 11, NM_013956.3; No. 12, NM_013957.3;
No. 13, NM_013958.3; No. 14, NM_013959.3; No. 15,
NM_013960.3; No. 16, NM_013962.2; and No. 17,
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leukemia viral oncogene homolog 3; Gene ID: 2065), two different
isoforms are described: No. 1, NM_001982.3 and No. 2,
NM_001005915.1. Primers were designed to cover most of the 17
isoforms of NRG1. For cDNA quantitation, one sixtieth of the reverse
transcriptase reaction was mixed with 0.5 μM gene-specific primers.
Primers were given as follows: NRG1 primer set 1 (binding all isoforms0
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HPRT1–5′- GCTATAAATTCTTTGCTGACCTGCTG-3′ (for-
ward) and 5′ AATTACTTTTATGTCCCCTGTTGACTGG-3′
(reverse) and Fast SYBR Green Master Mix (Applied Biosystems) to a
total volume of 12 μl. The polymerase chain reaction (PCR) was carried
out on a StepOnePlus instrument (Applied Biosystems, Darmstadt,
Germany), according to the manufacturer's instruction.
Kinase Selectivity Profiling
The kinase selectivity profiling was performed by Proteros
biostructures GmbH (Martinsried, Germany) according to the
company's standard operation procedure. The calculations of percent-
age of inhibition have been performed using three different types of
assays, namely, IMAP (Molecular Devices, Sunnyvale, CA), binding,
and HTRF assays (Molecular Devices, Sunnyvale, CA). The radar blot
in Figure 1D contains the data for the selectivity screening of compound
MPCD84111 against 36 protein kinases normalized to a maximal
inhibition of 100%.The experiments have been performed in triplicate.
IMAP assay. The IMAP assay (Molecular Devices, Sunnyvale,
CA) detects kinase activity in solution. A fluorescently labeled substrate
peptide is phosphorylated in the kinase reaction. After the reaction, a
binding solution containing large trivalent metal-based nanoparticles is
added, and the phosphorylated substrate binds to these beads. This
reduces the rotational speed of the substrate, which can be detected
using fluorescence polarization. The following kinases were used as
substrates: Abl, AKT1, AurA, Axl, Cyclin-dependent kinase 2 (CDK2),
CDK4, Serine/threonine-protein kinase Chk1/Checkpoint kinase-1
(CHK1), Kit, Met, Tyrosine-protein kinase CSK/C-Src kinase (CSK),
Fibroblast growth factor receptor 3 (FGFR3), Receptor-type tyrosine-
protein kinase FLT3/Fms-like tyrosine kinase 3 (FLT3), Inhibitor of
nuclear factor kappa-B kinase subunit beta (IKKβ), InsR, Interleukin-1
receptor-associated kinase 4 (IRAK4), Tyrosine-protein kinase JAK3/
Janus kinase 3 (JAK3), Mitogen-activated protein kinase 8/c-Jun
N-terminal kinase 1 (JNK1). Mitogen-activated protein kinase 3/
Extracellular signal-regulated kinase 1 (ERK1), Serine/threonine-
protein kinase PAK 1/p21-activated kinase 1 (PAK1), PAK4,
Platelet-derived growth factor receptor beta (PDGFRβ), Serine/
threonine-protein kinase pim-1 (PIM1), Protein kinase C alpha
type (PKCα), Serine/threonine-protein kinase PLK3/Polo-like
kinase 3 (PLK3), Ret, RockII, Src, Syc, Tie2, TrkA, Vascular
endothelial growth factor receptor 2 (VEGFR-2), and Death-associated
protein kinase 3/Zipper-interacting protein kinase (ZIPK).
Binding assay. The binding assay is based on reporter probes that
are designed to bind to the site of interest of the target protein. The
binding of the reporter probe to the protein results in the emission of anFigure 1. HER3 activation is a common feedback mechanism of Ax
contrast to BMS777607. (A) Inhibition of Axl phosphorylation was det
R428 by p-Tyr–Axl ELISA in NIH/3T3-Axl cells. IC50 values were calcula
in a dose-dependent manner, with an IC50 value of 0.006 μM for BMS
Inhibitors induce HER3 expression. Western blot analysis of MDA-MB
for 24 hours. BMS777607 and R428 caused an increase in pHER3
Treatment with all three Axl inhibitors leads to a six- to 7.5-fold up-regu
analysis of Western blots for pHER3 Y1289 and HER3. Mean values a
of HER3 in contrast to BMS777607. Western blot analysis of MDA-M
hours is shown. BMS777607 caused an increase in pHER3 Y1289 aft
induced a significant increase in protein expression of HER3 after 16
of 36 human kinases proves HER2 as a direct target of MPCD84111.
concentration of 10 μM. The plots indicate the percentages of inhibioptical signal. Compounds that bind to the same site as the reporter
probe displace the probe, causing signal diminution. Probe displace-
ment is calculated in percentage. Signal reflecting 100% probe
displacement is determined in the absence of enzyme, whereas 0%
probe displacement is measured in the absence of compound. The
reporter probe is used at a concentration reflecting its own Kd is the
equilibrium dissociation constant (probe) value. The following kinases
were used as substrates: Serine/threonine-protein kinase B-raf/v-Raf
murine sarcoma viral oncogene homolog B1 (BRAF), Epithelial
discoidin domain-containing receptor 1 (DDR1), and Serine/threo-
nine-protein kinase mTOR/Mammalian target of rapamycin (mTOR).
HTRF assay. This assay detects kinase activity with time-resolved
fluorescence transfer (FRET). A biotinylated, kinase-specific peptide
is phosphorylated in the kinase reaction. After the reaction, two
detection reagents are added: first, an antibody recognizing the
phosphorylated amino acid residue that is labeled with europium
cryptate as a FRET donor and second, streptavidin that binds to the
peptide through its biotin group and carries XL665 as a FRET
acceptor. If the substrate becomes phosphorylated, the close
proximity between the FRET donor and acceptor allows for the
measurement of the time-resolved FRET signal. The HER2 kinase
was analyzed by HTRF assay.
TKIs and Therapeutic Monoclonal Antibodies
Lapatinib and MPCD84111 were obtained from Vichem Chemie
Research Ltd (Budapest, Hungary). MPCD84111 is patented under
application example 12 from WO2011045084. BMS777607 and
R428 were kind gifts from Lead Discovery Center GmbH (LDC,
Dortmund, Germany). All inhibitors were dissolved in DMSO and
stored at room temperature in 10 mM stock solution. The therapeutic
monoclonal antibodies Herceptin and Erbitux were purchased from
the Max Planck Pharmacy (Martinsried, Germany).
Ligands and Batimastat
The recombinant human NRG1 (No. 396-HB-050) and batima-
stat (BB94, No. 2961) were purchased from R&D Systems GmbH.
Microscopy
Phase-contrast images were captured on a Axiovert 300 microscope
(Carl Zeiss, Jena, Germany) using MetaMorph (Molecular Devices,
Sunnyvale, CA).
Statistical Data Analysis
All assays were performed at least in triplicate. Mean values and
SEM are shown. Half maximal inhibitory concentration IC50 valuesl inhibitors, and MPCD84111 blocks phosphorylation of HER3 in
ermined 1 hour posttreatment with BMS777607, MPCD84111, and
ted by four-parameter log curve fit. Axl kinase activity was inhibited
777607, 0.027 μM for MPCD84111, and 0.043 μM for R428. (B) Axl
231 cells treated with 10 μM BMS777607, MPCD84111, and R428
Y1289 after 24 hours of treatment in contrast to MPCD84111.
lation of HER3 protein levels. The diagrams show the densitometric
nd SEM are shown (n= 3). (C) MPCD84111 blocks phosphorylation
B231 cells treated with 1 μM BMS777607 or MPCD84111 up to 48
er 6 hours of treatment in contrast to MPCD84111. Both inhibitors
hours of treatment. (D) The kinase selectivity profile against a panel
The selectivity profiling was performed in triplicate at a compound
tion for each individual kinase.
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Figure 2. Inhibition of the Axl RTK leads to up-regulation of HER3 phosphorylation. (A) Inhibition of Axl phosphorylation was determined 1
hour posttreatment with BMS777607 by p-Tyr–Axl ELISA in NIH/3T3-Axl cells. IC50 values were calculated by four-parameter log curve fit.
(B) Axl inhibition led to an up-regulation of HER3 phosphorylation as determined by the Human Phospho-RTK Array Kit. MDA-MB231 cells
were incubated with 1 μM BMS777607 for 24 hours or Axl-specific siRNA for 48 hours. The capture antibodies have been spotted in
duplicates. The coordinates in the membrane for EGFR, HER2, Met, HER3, HER4, InR, IGF1R, and Axl are highlighted by rectangles. The
corresponding antibody names are labeled at the bottom of the three displayed membranes from left to the right. (C) Validation of HER3
phosphorylation by HER3 immunoprecipitation with a HER3-specific antibody (Millipore, No. 05-390) and the Western blot for p-Tyr. The
site-specific pHER3 Y1289 antibody displayed the same up-regulation of HER3 phosphorylation in Western blot experiments after
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phosphorylation by Western blot analysis of MDA-MB231 cells treated with Axl-specific siRNA for 48 hours or with 1 or 10 μM
BMS777607 for 24 hours. The depletion of Axl kinase by siRNA was confirmed by anti-Axl Western blot analysis. Independent of the
conditions, an increase of pHER3 Y1289 levels was evident in contrast to control treatments. Tubulin served as loading control. (E) Met-
specific knockdown displayed no effect on pHER3 Y1289 levels compared to control siRNA treatment. The phosphorylation of HER3
Y1289 was induced by 10 μM BMS777607 treatment for 24 hours independent of Met expression. The depletion of Met kinase from the
cells was confirmed byWestern blot analysis performed on cell lysates harvested 48 hours after Met-specific siRNA transfection. Tubulin
served as loading control.
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parameter curve fitting. For statistical analysis, we performed a
Mann-Whitney test or a Kruskal-Wallis test in combination withDunn multiple comparison posttest using GraphPad Prism 5
(GraphPad Software, Inc, La Jolla, CA). Differences with *P b .05,
**P b .01, and ***P b .001 were considered as statistically significant.
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Figure 3. Inhibition of Axl leads to phosphorylation of HER3 in multiple cell lines and correlates with low basal AKT phosphorylation. (A)
Western blot analysis of MDA-MB231, Hs578T, Ovcar8, and SKOV-3 cells treated with 10 μM BMS777607 for 24 hours. A significant
increase of pHER3 Y1289 levels was evident in MDA-MB231 and Ovcar8 cells in contrast to Hs578T and SKOV-3 cells. Tubulin served as
loading control. (B) Western blot analysis of MDA-MB231, Hs578T, Ovcar8, and SKOV-3 cells treated with Axl-specific siRNA for 48 hours.
A significant increase of pHER3 Y1289 levels was evident in MDA-MB231 and Ovcar8 cells in contrast to Hs578T and SKOV-3 cells.
Tubulin served as loading control. (C) Low basal levels of AKT S473 phoshorylation correlate with induction of pHER3 Y1289 after Axl
inhibition by 10 μM BMS777607 and Axl knockdown with siRNA. The levels of basal AKT S473 phosphorylation for the indicated 20 cell
lines are shown in ascending order on the abscissas axis. In parallel, we determined the up-regulation of HER3 phosphorylation of those
20 cell lines by Western blot analysis for pHER3 Y1289. The cell lines displaying activation of HER3 after Axl depletion were marked with
red triangles on the top. The cell lines without HER3 response to Axl inactivation were marked with blue triangles. A positive correlation
between a low basal phosphorylation of AKT S473 and the induction of HER3 phosphorylation was evident as 7 of 10 cell lines with low
pAKT S473 levels, but only 2 of 10 cell lines with high pAKT S473 levels responded with up-regulation of pHER3 Y1289 to the inhibition of
Axl by BMS777607 or Axl-specific siRNA. AKT phosphorylation was normalized to the highest values represented by SKOV3 cells (100%).
Mean values and SEM are shown (n = 3).
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Inhibition of the Axl RTK Leads to Up-Regulation of HER3
Phosphorylation
The Axl RTK activates prosurvival and metastatic pathways, and
Axl overexpression was shown to correlate with aggressive tumor
behavior. Therefore, we evaluated multiple TKI as potential Axl
inhibitors and finally selected BMS777607 as the most potent Axl
inhibitor published up to now. BMS777607 is currently undergoing
phase I clinical trials and was originally described as a Met TKI.
However, BMS777607 displays a higher affinity to Axl RTK (IC50 of1.1 nM) than to Met (IC50 of 3.9 nM) as published by Schreoder et
al., 2009 [24]. In the first step, we validated the efficiency of
BMS777607 to inhibit Axl phosphorylation by treating Axl-
overexpressing NIH/3T3-Axl cells for 1 hour with serially diluted
compound concentrations. Subsequently, we performed a phospho-
Axl–specific ELISA and calculated the IC50 values by applying a
four-parameter logistic curve fit. BMS777607 inhibits Axl autopho-
sphorylation at low nanomolar concentrations, displaying an IC50
value of 0.006 μM as shown in Figure 2A. This NIH/3T3-Axl cell
line was generated by Axl cDNA transfection because it represents a
useful tool to screen the efficacy of Axl inhibitors.
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model system to study the effect of Axl inhibitors on human cancer
cells. We selected the triple-negative breast cancer cell line MDA-
MB231, first, because it is characterized by overexpression of the Axl
RTK, and second, because multiple studies proved in MDA-MB231A B
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sitometric analysis of Western blots for pHER3 Y1289 and HER3.
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hours after exposure of MDA-MB231 cells to 1 μM BMS777607,
phosphorylation of Axl and Met decreased significantly, whereas
phosphorylation of HER3 was markedly enhanced. The phosphory-
lation of the other three HER family members (EGFR, HER2, and
HER4) remained unchanged (Figure 2B). In contrast to the treatment
with 1 μM BMS777607, the Axl-specific siRNA knockdown
additionally induced the phosphorylation of the insulin receptor
(InR) and a slight up-regulation of the insulin-like growth factor 1
receptor (IGF1R) and of HER2 levels (Figure 2B). Unfortunately, we
were not able to verify the phosphorylation of InR, IGF1R, and HER2
in Western blot experiments (data not shown).
To validate this Axl-specific siRNA-induced HER3 phosphoryla-
tion, we performed an immunoprecipitation for HER3 from MDA-
MB231 cell lysates under the same conditions as described for the
RTK array. Tyrosine phosphorylation of HER3 was quantified by
Western blot analysis using a homemade anti–p-Tyr antibody. The
same induction of HER3 phosphorylation was evident with the site-
specific pHER3 Y1289 antibody (Figure 2C). pHER3 Y1289 is a
PI3K-binding site, and this phosphorylation was shown to be
essential for PI3K/AKT signaling cascade activation [28]. Therefore,
we used this site-specific antibody for all subsequent experiments.
To further validate the RTK array results and to elucidate the
impact of serum on HER3 phosphorylation, we treated MDA-
MB231 cells with Axl-specific siRNA to induce depletion of Axl
protein either under full-serum conditions (10% FBS) or under
starving conditions (0% FBS). The depletion of Axl kinase from the
cells was confirmed by Western blot analysis performed on cell lysates
harvested 48 hours after Axl-specific siRNA transfection. Indepen-
dent of the serum conditions, a significant increase of pHER3 Y1289
levels was evident in contrast to control siRNA treatment
(Figure 2D). The treatment with 1 and 10 μM BMS777607 for 24
hours led also to an enhancement of HER3 phosphorylation in a
concentration-dependent manner (Figure 2D).
As BMS777607 was originally published as Met inhibitor but also
targets Axl RTK very potently at low nanomolar concentrations, it
was necessary to elucidate a possible role of Met in the up-regulation
process of phospho-HER3 [24]. Therefore, we used Met-specific
siRNA to deplete the protein from MDA-MB231 cells. The Met
knockdown was confirmed by Western blot analysis 48 hours after
Met-specific siRNA transfection. Met knockdown displayed no effect
on pHER3 Y1289 levels compared to control siRNA treatment
(Figure 2E). Additionally, independent from the Met knockdown,
the treatment with 10 μM BMS777607 for 24 hours increased the
phosphorylation level of HER3. On the basis of this result, we
conclude that Met inhibition is not related to the up-regulation of
HER3 phosphorylation.
To sum up, HER3 remained the only validated and consistently
up-regulated RTK after treatment with BMS777607 or knockdown
with Axl-specific siRNA in MDA-MB231 cells.
Inhibition of Axl RTK Leads to Phosphorylation of HER3
in Multiple Cell Lines and Correlates With Low Basal
AKT Phosphorylation
Because we had shown that pHER3 is an activating feedback
mechanism on Axl inhibition inMDA-MB231 cells, we asked if this is a
general phenomenon in Axl-overexpressing tumor cells. Therefore, we
analyzed the activation of HER3 in different breast and ovary cancer cell
lines expressing Axl. First, we blocked Axl activity pharmacologicallywith 10 μM BMS777607 (Figure 3A), and second, we depleted Axl
protein by Axl-specific siRNA (Figure 3B). Phospho-HER3 was
inducible after Axl protein depletion as well as after inhibition of
phosphorylation by treatment with 10 μM BMS777607 in MDA-
MB231 and Ovcar8 cells but not in Hs578T and SKOV-3 cells
(Figure 3, A and B). From this finding, we concluded that Axl
expression itself is not a biomarker for the induction of a HER3
feedback loop.
To further characterize the HER3 activation loop, we analyzed 20
different Axl-expressing cell lines originating from brain, breast,
ovary, cervix, lung, and pancreatic tumors. Knowing that the AKT
signaling pathway is influenced by Axl RTK, we performed phospho-
AKT S473 ELISAs to determine the basal AKT phosphorylation
levels. The levels of pAKT S473 are shown in ascending order on the
axis of abscissas in Figure 3C. In parallel, we determined the
activation of HER3 in those 20 cell lines after treatment with 10 μM
BMS777607 and Axl-specific siRNA by Western blot analysis with
the pHER3 Y1289 antibody. The cell lines displaying activation of
HER3 after Axl depletion were marked with red triangles on the top
of Figure 3C. The cell lines without HER3 response to Axl
inactivation were marked with blue triangles. Thereby, we discovered
a positive correlation between a low basal phosphorylation of AKT
S473 and the induction of HER3 activation on Axl inhibition by
BMS777607 and Axl-specific siRNA treatment. Seven of 10 cell lines
with low pAKT S473 levels but only 2 of 10 cell lines with high
pAKT S473 levels responded with up-regulation of pHER3 Y1289
after inhibition of Axl by BMS777607 or Axl-specific siRNA
treatment (Figure 3C).
From these results, we conclude that inhibition of Axl induces an
activation feedback loop of HER3, in various tumor types,
characterized by low basal AKT S473 phosphorylation and by a
high dependency on Axl/PI3K/AKT signaling.
Inhibition of the Axl RTK Activates HER3 Transcription but
Not of Its Ligand NRG1
Next, we performed quantitative PCR to determine the levels of
HER3 mRNA. Therefore, we treated MDA-MB231 cells with 10
μM BMS777607 and harvested them at different time points. A
significant induction of HER3 mRNA production became evident
after 16 hours of treatment reaching a 3.9-fold level, whereas the
maximum increase of HER3 mRNA was achieved after 48 hours
reaching 5.9-fold values (Figure 4A). As breast cancer cells often
express high levels of HER RTK activating ligands [29], we
performed quantitative PCR and ELISA analysis of the HER3
ligand NRG1 to compare the relative levels after treatment with 10
μM BMS777607. The Gene database search on National Center for
Biotechnology Information platform revealed 17 different NRG1
isoforms in H. sapiens (Gene ID: 3084). Due to the fact that NRG1
appears in different isoforms deriving from the NRG1 gene by
alternative splicing, we used two different primer sets for
quantitative PCR analysis. One primer set binds to the mRNA of
all isoforms except of isoforms No. 2 and No. 14. The second
primer set binds to the mRNA of isoforms No. 2, No. 15, and No.
17. In this way, we were able to cover all isoforms with the
exception of isoform No. 14. NRG1 mRNA expression was
detectable in MDA-MB231 cells, but it was induced only reaching
values between 1.2- or 1.5-fold within 48 hours (Figure 4, B and C).
Accordingly, we excluded NRG1 mRNA up-regulation as being
responsible for HER3 activation.
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Consumption of NRG1
Although we did not expect an up-regulation of NRG1 ligand on
the basis of the quantitative PCR results, we analyzed NRG1 protein
levels in the supernatant of BMS777607-treated MDA-MB231 cells
by NRG1-ELISA. Strikingly, the levels of NRG1 protein dropped in
the supernatant of 10 μM BMS777607-treated MDA-MB231 cells
in a time-dependent manner compared to DMSO-treated control
levels from 97% after 1 hour to less than 1% after 48 hours
(Figure 4D). To determine if there is any connection between the
decrease of NRG1 ligand in the supernatant and HER3 activation, we
treated the MDA-MB231 cells in a time course experiment up to 48
hours with 10 μM BMS777607 and analyzed in parallel the
supernatant by Western blot. Consistent with the previous results,BMS777607 caused a 4.2-fold activation of pHER3 Y1289 after 6
hours of treatment (Figure 4E). The activation of pHER3 Y1289
correlated with the decrease of NRG1 in the supernatant (Figure 4D).
The climax of 11.1-fold HER3 activation was reached after 24 hours
of compound treatment and decreased at the 48-hour time point.
Parallel to the pHER3 Y1289 decrease, NRG1 levels of the
supernatant approximated the background level of the NRG1
ELISA assay after 48 hours. At the same time, we proved that the
7.8- to 8.8-fold increased expression of HER3 protein, after 16 to 48
hours of treatment, results from the elevated level of HER3 mRNA as
shown in Figure 4A. Simultaneously, BMS777607 was able to inhibit
phosphorylation of AKT S473 constantly for up to 48 hours.
However, the phosphorylation of HER3 does not result in a
downstream activation of pAKT S473. These results reveal that Axl
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and to the NRG1 ligand–dependent phosphorylation of HER3.
Additionally, these results are in line with the mechanism of AKT
inhibition–dependent transcription of HER3 described recently by
Chandarlapty et al., 2011 and Chakrabarty et al., 2012 [30,31].
HER3 Induction is a Common Feedback Mechanism
of Axl Inhibitors
Because we could show that induction of pHER3 is part of an
activation feedback mechanism induced by BMS777607, we asked
whether this is a general phenomenon of Axl inhibitors. Therefore, we
compared BMS777607 to R428, a recently described Axl inhibitor
[25], and an Axl inhibitor recently developed by our group, namely,
MPCD84111. First, we determined the activity of these Axl TKIs in
NIH/3T3 Axl-overexpressing cells. For this reason, we treated the
cells for 1 hour with serially diluted compound concentrations of
BMS777607, MPCD84111, and R428 and subsequently performed
a phospho-Axl–specific ELISA to calculate the IC50 values by
applying a four-parameter logistic curve fit. As shown in Figure 1A,
the compounds inhibited Axl phosphorylation at nanomolar
concentrations, displaying IC50 values for BMS777607 of 0.006
μM, MPCD84111 of 0.027 μM, and R428 of 0.043 μM.
Next, we analyzed if MPCD84111 and R428 have the same
impact on the HER3 feedback loop as BMS777607 in MDA-MB231
cells. Interestingly, treatment with 10 μM BMS777607 and 10 μM
R428 induced the phosphorylation of HER3 (6.7- and 2.8-fold),
whereas 10 μM MPCD84111 prohibited the phosphorylation of
HER3 by 68% in comparison to DMSO control within 24 hours
(Figure 1B). We could also demonstrate that 10 μM BMS777607
and 10 μM R428 as well as 10 μM MDCD84111 induce HER3
expression 6.1-, 7.5-, and 7.4-fold in comparison to DMSO
treatment. Our data reveal that the transcriptional feedback loop of
HER3 was initiated similarly by BMS777607, R248, and
MPCD84111, even though MPCD84111 was able to block
phosphorylation of HER3 Y1289 efficiently.Figure 5. Inhibition of HER2 blocks HER3 phosphorylation in triple-ne
MPCD84111. MPCD84111 inhibits phosphorylation of HER2 in con
cells. Phosphorylation of HER2 Y1248 was analyzed 1 hour after a
compounds were used in three-fold serial dilutions starting with 10
block HER3 phosphorylation in MDA-MB231 cells. Representative W
for 24 hours compared to DMSO-treated control cells are shown. Cells
Erbitux, 10 μg/ml Herceptin, or 5 μM lapatinib for 2 hours. One hundr
polyacrylamide gel electrophoresis, blotted, and probed with corresp
and Tubulin as loading control. BB94, Herceptin, and lapatinib
phosphorylation in contrast to Erbitux. (C) EGFR in combination with
Y1289 levels compared to control siRNA treatment. MDA-MB231 cells
and HER2-specific siRNA for 48 hours. Subsequently, the phosphoryl
for 24 hours. Only HER3 and the combination of EGFR and HER2
knockdown leads to a less pronounced reduction of HER3 phosphor
activity by 1.4-fold. The depletion of EGFR, HER2, and HER3 from t
as loading control. The diagram shows the densitometric analysis of
(n = 3). (D) MDA-MB231 cells were treated with 10 μM BMS77760
phosphorylation of HER3. The HER2 RTKwas immunoprecipitated wit
2 mg of total lysate. Western blots for p-Tyr and total HER2 are show
compared to DMSO-treated control, and 50 ng/ml NRG1 further enh
immunoprecipitation of HER2. MDA-MB231 cells were treated
immunoprecipitated with a homemade HER2-specific antibody (clone
aswell as for Tubulin are shown. Twentymicrograms of the total lysate
the immunoprecipitation. BMS777607 treatment increased the phosph
NRG1 further enhanced the phosphorylation level. Therefore, HER2 rem
MDA-MB231 cells.To elucidate these results in more detail, we treated MDA-MB231
cells in a time course experiment for up to 48 hours with 1 μM
BMS777607 or MPCD84111 and analyzed the cell lysates by
Western blot. In contrast to BMS777607, MPCD84111 inhibited
the phosphorylation of HER3 Y1289 during the entire time course
(Figure 1C). Interestingly, both inhibitors increased the total protein
levels of HER3 after 16 hours of treatment. It was published earlier by
Myatt and Lam, 2007 that inhibition of AKT has an impact on the
expression and activity of the Forkhead box protein O (FoxO) family
members [32]. Therefore, the induction of HER3 RTK expression
might result from FoxO-dependent transcription. Our data point out
that the phosphorylation of HER3 is blocked by MPCD8411
independently from transcription cascade of HER3 and might result
from a direct inhibition by the compound.
MPCD84111 Inhibits the Dimerization Partner
for HER3
Subsequently, we addressed the question why MPCD84111, but
not BMS777607, inhibits phosphorylation of HER3. It is widely
accepted that HER3 has an impaired kinase activity. Because of this
reason, activation of the HER3 RTK occurs only after the
dimerization with other RTKs, such as HER2 or EGFR [33]. We
asked if MPCD84111-dependent inhibition of HER3 phosphoryla-
tion (Figure 1, B and C) might be a result of blocking HER2 as a
heterodimerization partner for HER3. Therefore, we determined the
kinase selectivity profile of MPCD84111 using three different types
of assays, namely, IMAP, binding, and HTRF assays. The kinase
profile of BMS777607 was published earlier by Schroeder et al., 2009
[24]. The kinase profile of MPCD84111 displayed an inhibition of
Axl as well as Met, Src, Abl, Kit, Ret, PDGFRβ, Tie2, VEGFR-2, and
DDR1 with efficacy of 100% when used at 10 μM concentration
(Figure 1D). The comparison of both kinase selectivity profiles
identified common targets of BMS777607 and MDCD84111 such
as Axl, Met, Kit, PDGFRβ, Tie2, AuroraA/B, and VEGFR-2. In
contrast to BMS777607, MPCD84111 uniquely targets HER2, agative breast cancer cells. (A) Validation of HER2 being a target of
trast to BMS777607 as demonstrated on HER2-expressing MCF7
ddition of BMS777607 and MPCD84111 by Western blot. Both
μM. Tubulin served as loading control. (B) Herceptin and lapatinib
estern blots of MDA-MB231 cells treated with 10 μM BMS777607
were additionally incubated with 5 μMBB94 (batimastat), 10 μg/ml
ed micrograms of lysate was subjected to sodium dodecyl sulfate–
onding antibodies for pHER3 Y1289, HER3, pAKT S473, pERK1/2,
were able to suppress the BMS777607-induced HER3 Y1289
HER2-specific knockdown exhibits a significant effect on pHER3
were treated with EGFR, HER2, HER3, and a combination for EGFR
ation of HER3 Y1289 was induced by 10 μMBMS777607 treatment
siRNA blocked HER3 phosphorylation completely. HER2-specific
ylation, and EGFR-specific knockdown even induces pHER3 y1289
he cells was confirmed by Western blot analysis. Tubulin served
Western blots for pHER3 Y1289. Mean values and SEM are shown
7 for 24 hours to further validate the involvement of HER2 in the
h a commercial HER2-specific antibody (Millipore, No. 06-562) from
n. BMS777607 treatment increased the phosphorylation of HER2
anced the phosphorylation level. (E) Validation of HER2 activity by
with 10 μM BMS777607 for 24 hours. The HER2 RTK was
13D1B1) from 2 mg of total lysate. Western blots for p-Tyr, HER2,
was used for the TubulinWestern blot analysis as loading control for
orylation of HER2 compared to DMSO-treated control, and 50 ng/ml
ains a hardly detectable, but active dimerization partner for HER3 in
312 Activation of HER3 Interferes with Axl RTK Inhibitors Torka et al. Neoplasia Vol. 16, No. 4, 2014dimerization partner of HER3 (Figure 1D). This finding implicates
that blocking of HER3 phosphorylation by MPCD84111 might be
achieved by inhibition of HER2.
Inhibition of HER2 Blocks HER3 Phosphorylation in
Triple-Negative Breast Cancer Cells
In breast cancer cells with HER2 gene amplification, HER2 is the
main kinase that phosphorylates HER3 [34]. As BMS777607 in
contrast to MPCD84111 does not affect the catalytic activity of
HER2 as demonstrated in MCF7 cells expressing HER2 (Figure 5A),
we assumed that in HER2 low-expressing MDA-MB231 cells, HER2
might also act as the kinase maintaining phosphorylation of HER3 on
inhibition of Axl as well.
Therefore, we examined the effect of BMS777607 in combination
with either 10 μg/ml HER2-blocking antibody Herceptin, 5 μMEGFR/HER2 TKI lapatinib, or 5 μM the broad spectrum matrix
metalloprotease inhibitor BB94 (batimastat). In MDA-MB231 cells,
all of these combinations effectively inhibited phosphorylation of
HER3, in contrast to the treatment with 10 μg/ml Erbitux
(Figure 5B). Particularly, the specific blocking of HER2 by the
monoclonal antibody Herceptin as well as lapatinib suggested that
HER2 plays a significant role in maintaining phosphorylation of
HER3 in MDA-MB231 cells. It is well known that active ligands of
the HER family are proteolytically cleaved by metalloproteases and
afterwards released from the cell surface [35]. BB94 (batimastat) is a
broadband inhibitor of the Disintegrin and metalloproteinase
domain-containing protein ADAM family of metalloproteases and
blocks shedding of EGFR ligands [36,37]. Inhibition of HER3
phosphorylation by 5 μM BB94 underlined our findings that HER3
is activated by an extracellular mechanism. BMS777607 consistently
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on the Mitogen-activated protein-kinase pathways as proven by
pERK1/2 Western blot analysis (Figure 5B).
Knowing that lapatinib was most efficient in blocking HER3
phosphorylation, we evaluated the impact of EGFR and HER2 on
HER3 phosphorylation by siRNA experiments. Therefore, we
depleted EGFR, HER2, HER3, and EGFR in combination with
HER2 from MDA-MB231 cells by siRNA knockdown and
subsequently induced HER3 phosphorylation by 10 μM BMS
treatment for 24 hours (Figure 5C). Only HER3 siRNA and the
combination of EGFR and HER2 siRNA treatment blocked HER3
phosphorylation, completely exhibiting less than 5% of phosphor-
ylation compared with control siRNA treatment. Comparable to
Herceptin, HER2-specific siRNA treatment remained a residual
HER3 phosphorylation of 22% (Figure 5C).
Although MDA-MB231 cells represent a prototype of triple-
negative breast cancer cell lines characterized by the loss of HER2
expression, we investigated HER2 as one of the probable dimerization
partners of HER3. To elucidate in more detail the phosphorylation
status of HER2 in triple-negative breast cancer cells, we performed
immunoprecipitation experiments with a vast protein amount of 2
mg. We treated MDA-MB231 cells with 10 μM BMS777607 for 24
hours, and we further enhanced the phosphorylation of HER2 by
stimulation with 50 ng/ml NRG1. The HER2 RTK was
immunoprecipitated with a homemade anti-HER2–specific antibody
(clone 13D1B1) or a commercial anti-HER2 antibody (Millipore,
No. 06-562). The subsequent Western blot analysis for p-Tyr
resulted in a slight, but reproducible, induction of tyrosine
phosphorylation after BMS777607 treatment and NRG1 stimulation
(Figure 5, D and E).
Hence, we assume that this minimal amount of HER2
phosphorylation might contribute to the pronounced HER3
activation and thereby maintains the feedback loop counteracting
Axl inhibitor treatment. Additionally, lapatinib emerged as the most
efficient treatment strategy for inhibition of HER3 phosphorylation.Figure 6. Exogenous application of NRG1 rescues AKT phosphorylatio
inhibition of cell viability by BMS777607. Cell viability of MDA-MB
treatment under starving conditions (0% FBS). Cells were incubated
and without 50 ng/ml NRG1. Addition of NRG1 completely compensat
The DMSO control does not react to NRG1 stimulation. Mean values a
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was measured by CellTiter-Glo assay after 72 hours of treatment.
MPCD84111 using starving conditions (0% FBS). Cell viability was re
Ovcar8 cells. Mean values and SEM of three independent experimen
were considered statistically significant (Mann-Whitney test). (C) BMS
phosphorylation. Western blot analysis of MDA-MB231 cells is show
μM BMS777607 and 5 μM lapatinib relative to DMSO control for 24 h
significant increase of the pHER3 Y1289 levels was evident after
phosphorylation of AKT S473 to 24%. Additional NRG1 stimula
phosphorylation. The combination of BMS777607 and lapatinib block
loading control. The diagrams show the densitometric analysis of Wes
are shown (n= 3). (D) BMS777607 and lapatinib exhibit a synergistic
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Even though complete recovery of pAKT S473 was not achieved
with a pharmacological dose of 1 μM BMS777607, the feedback up-
regulation of HER3 expression and HER3 phosphorylation was
clearly evident, further suggesting that inhibition of the Axl/PI3K/
AKT pathway leads to the reactivation of HER3 (Figure 4E). These
data imply that HER3 phosphorylation partially restores the
prosurvival and proliferation signaling that, in turn, may limit the
effect of Axl inhibitors. To support this hypothesis, we performed
rescue experiments in combination with cell viability assays. MDA-
MB231 cells were treated with pharmacological concentrations of
BMS777607 under starving conditions for 72 hours. Addition of the
HER3 ligand (50 ng/ml NRG1) completely compensated the
inhibitory effect of 0.1 and 1 μM BMS777607 on cell viability. In
contrast, the cell viability of the untreated cells was not affected by
NRG1 stimulation (Figure 6A). The compensatory up-regulation of
HER3 expression and partial maintenance of HER3 phosphorylation
on inhibition of Axl suggested that combined inhibition of Axl and
HER2/HER3 could synergistically inhibit tumor cell viability.
Monolayer cell cultures represent oversimplified models for tumor
studies, due to the loss of extracellular matrix rigidity on artificial
plastic surfaces and high serum concentrations. These conditions
poorly mimic the tumor cell biology in vivo. A more robust and
reproducible test system is the three dimensional (3D) spheroid
culture. To test the combined inhibition of Axl and HER2/HER3 on
tumor cell viability, we used these 3D spheroid cultures.
We treated two Axl-expressing cell lines, namely MDA-MB231
and Ovcar8, with MPCD84111 and with a combination of BMS and
lapatinib, to elucidate the hypothesis that an inhibition of Axl and
HER2/HER3 might be essential for treatment of Axl overexpressing
cells. First, we proved the efficacy of 1 μM MPCD84111 in contrast
to 1 μM BMS777607 treatment on MDA-MB231 and Ovcar8 cells.
One micromolar MPCD84111 significantly inhibited cell viability to
37% in MDA-MB231 spheroids and to 42% in Ovcar8 spheroids inn and cell viability. (A) Exogenous application of NRG1 rescues the
231 cells was measured by CellTiter-Glo assay after 72 hours of
with increasing concentrations of BMS777607 (0.1, 1, 10 μM) with
es the proliferation inhibitory function of 0.1 and 1 μMBMS777607.
nd SEM of three independent experiments are shown. Differences
significant (Mann-Whitney test; ns, nonsignificant). (B) Cell viability
rast to BMS777607. Cell viability of MDA-MB231 and Ovcar8 cells
3D spheroids were incubated with 1 µM BMS777607 or 1 µM
duced to 37% by MPCD84111 in MDA-MB231 cells and to 43% in
ts are shown. Differences with *P b .05, **P b .01, and ***P b .001
777607 and lapatinib exhibit a synergistic inhibitory effect on HER3
n. Cells were treated with 1 μM BMS777607 or a combination of 1
ours with or without 50 ng/ml NRG1 stimulation for 15 minutes. A
BMS777607 treatment. BMS777607 treatment suppressed the
tion enhances HER3 phosphorylation and restores pAKTS473
s completely the HER3 and AKT phosphorylation. Tubulin served as
tern blots for pHER3 Y1289 and pAKT S473. Mean values and SEM
inhibitory effect on HER3 phosphorylation. Western blot analysis of
a combination of 1 μM BMS777607 and 5 μM lapatinib relative to
for 15 minutes. A 2.4-fold increase of the pHER3 Y1289 levels was
sphorylation treatment completely rescued AKT phosphorylation.
horylation. The combination of BMS777607 and lapatinib blocks
oading control. The diagrams show the densitometric analysis of
EM are shown (n = 3).
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of 97% in MDA-MB231 and 92% in Ovcar8 in comparison to
DMSO-treated controls (Figure 6B).Second, we proved the complete inhibition of HER3 phosphory-
lation by combined treatment of 1 μM BMS777607 and 5 μM
lapatinib inMDA-MB231 and Ovcar8 cells. Additionally, we analyzed
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lead to the reconstitution of the AKT signaling pathway.
One micromolar BMS777607 leads to up-regulation of total HER3
protein levels and to a six-fold induction of HER3 phosphorylation
after 24 hours of treatment in MDA-MB231 cells (Figure 6C). The
phospho-AKTS473 levels are reduced to 24% compared with DMSO-
treated cells, and additional stimulation with 50 ng/ml NRG1 restores
pAKTS473 signal to DMSO control levels. The combination of 1 μM
BMS777607 and 5 μM lapatinib inhibited HER3 and AKT
phosphorylation to 0.9%, respectively, 6.1% in comparison to
BMS777607 single treatment. Especially, NRG1 ligand stimulation
was not able to induce HER3 phosphorylation any more than in
contrast to DMSO (two-fold induction) and 1 μM BMS777607
treatment (13-fold induction). HER2 phosphorylation was below
detection threshold in MDA-MB231 cells due to the low expression
level of HER2 in this cell line (Figure 6C).
TheOvcar8 cells react to 1μMBMS777607 treatment, analogous to
MDA-MB231, by up-regulation of totalHER3protein levels and a 2.4-
fold HER3 phosphorylation compared to DMSO-treated cells. This
HER3 phosphorylation results in a 1.4-fold induction of AKT
phosphorylation. Additional 50 ng/ml NRG1 ligand stimulation
leads in a 10- or 17.8-fold HER3 phosphorylation in DMSO control
and 1 μM BMS777607-treated cells. The combined treatment with 1
μM BMS777607 and 5 μM lapatinib completely prevents HER3 and
AKT phosphorylation and additionally prohibits the activation by
NRG1 ligand. In Ovcar8 cells, HER2 Y1248 exhibits an identical
phosphorylation pattern to pHER3 Y1289, emphasizing the impor-
tance of the HER2/HER3 heterodimer in maintaining the Her3
phosphorylation in cell lines with significant HER2 levels (Figure 6D).
We conclude that BMS777607-induced HER3 phosphorylation is
able to rescue or at least stabilizes theAKT signaling inOvcar8 andMDA-
MB231 cells, and vice versa, a combination of 1 μMBMS777607 and 5
μM lapatinib completely inhibits HER3 and AKT phosphorylation.Figure 7. Pharmacological inhibition of Axl sensitizes for lapatinib. (A) B
cell viability. Cell viability of MDA-MB231 cells was measured by
spheroids were incubated with 1 μM BMS777607, 5 μM lapatinib, or
starving conditions (0% FBS). Cell viability was reduced to 49.5% by t
to either compound administered separately. Mean values and SEM o
.05, **P b .01, and ***P b .001 were considered statistically signifi
lapatinib exhibit an additive cell viability inhibition effect. Cell viability o
treatment. Ovcar8 3D spheroids were incubated with 1 μM BMS7776
DMSO control under starving conditions (0% FBS). Cell viability was
BMS777607 compared to either compound administered separate
shown. Differences with *P b .05, **P b .01, and ***P b .001
nonsignificant). (C) Representative phase-contrast images of MDA-M
μMBMS777607, 5 μM lapatinib, or a combination of both compounds
hours. Scale bars indicate 100 μm. (D) Representative phase-contra
with 1 μM BMS777607, 5 μM lapatinib, or a combination of both co
FBS) for 72 hours. Scale bars indicate 100 μm. (E) Validation of the sy
cell viability. Cell viability of MDA-MB231 cells was measured by
spheroids were incubated with 1 μM BMS777607, 5 μM lapatinib, or
full-serum conditions (10% FBS). Inhibition of cell viability was signific
BMS777607 compared to either compound administered separately.
Differences with *P b .05, **P b .01, and ***P b .001 were considere
Validation of synergistic inhibitory effect by knockdown of Axl and H
specific siRNA, HER3-specific siRNA, or a combination of both siRN
grown for 72 hours under full-serum conditions (10% FBS), and cell via
was significantly increased to 22% by a combination of Axl-spec
transfected separately. Mean values and SEM of five independent exp
b .001 were considered statistically significant (Kruskal-Wallis test; nPharmacological Inhibition of Axl Sensitizes for
Lapatinib Treatment
We further tested the combined inhibition of Axl and HER2/
HER3 on tumor cell viability in 3D spheroid cultures of MDA-
MB231 and Ovcar8 cells. Therefore, we treated MDA-MB231 3D
spheroids with 1 μM BMS777607 and 5 μM lapatinib and assessed
their viability under starving conditions (0% FBS). Cell viability was
significantly reduced up to 50% by a combination of 1 μM
BMS777607 and 5 μM lapatinib compared to the effect of either
inhibitor administered alone (Figure 7A). The cell viability of Ovcar8
cell spheroids was significantly inhibited by 5 μM labatinib and the
combination of 1 μM BMS777607 and 5 μM lapatibnib. The cell
viability was inhibited to 56% by the combination of 1 μM
BMS777607 and 5 μM lapatinib (Figure 7B).
The images of Figure 7, C and D, visualize the spheroids formed
after 72 hours in Matrigel. Ovcar8 cell spheroids react more sensitively
to 5 μM lapatinib treatment alone due to the fact of higher HER2
expression levels and resulting dependency on HER2 signaling.
Analogous but less pronounced results were achieved with MDA-
MB231 3D spheroids cultured under full-serum conditions (10%
FBS). The cell viability of MDA-MB231 spheroids decreased
significantly under full-serum conditions by combination treatment
with 1 μM BMS777607 and 5 μM lapatinib. To better present the
differences in cell viability, we displayed the inhibition of cell viability
in Figure 7, E and F. The cell viability of MDA-MB231 3D
spheroids was not significantly affected by 1 μM BMS777607 or 5
μM lapatinib alone, whereas MDA-MB231 3D spheroids treated
with the TKI combination displayed a statistically significant
reduction in viability of 24% (Figure 7E). To underline the efficacy
of combined targeted therapies toward Axl and HER3, we performed
siRNA experiments to knockdown Axl and HER3 (Figure 7F).
Analogous to the pharmacological inhibition, the cell viability of
MDA-MB231 3D spheroids was not significantly affected by AxlMS777607 and lapatinib exhibit a synergistic effect on inhibition of
CellTiter-Glo assay after 72 hours of treatment. MDA-MB231 3D
a combination of both compounds relative to DMSO control under
he combination of 5 μM lapatinib and 1 μM BMS777607 compared
f three independent experiments are shown. Differences with *P b
cant (Kruskal-Wallis test; ns, nonsignificant). (B) BMS777607 and
f Ovcar8 cells wasmeasured by CellTiter-Glo assay after 72 hours of
07, 5 μM lapatinib, or a combination of both compounds relative to
reduced to 56% by the combination of 5 μM lapatinib and 1 μM
ly. Mean values and SEM of three independent experiments are
were considered statistically significant (Kruskal-Wallis test; ns,
B231 spheroids. MDA-MB231 3D spheroids were incubated with 1
relative to DMSO control under starving conditions (0% FBS) for 72
st images of Ovcar8 spheroids. Ovcar8 spheroids were incubated
mpounds relative to DMSO control under starving conditions (0%
nergistic inhibitory effect of BMS777607 and lapatinib treatment on
CellTiter-Glo assay after 72 hours of treatment. MDA-MB231 3D
a combination of both compounds relative to DMSO control under
antly increased to 24% by a combination of 5 μM lapatinib and 1 μM
Mean values and SEM of six independent experiments are shown.
d statistically significant (Kruskal-Wallis test; ns, nonsignificant). (F)
ER3 on cell viability. MDA-MB231 cell were transfected with Axl-
As for 48 hours. Subsequently, MDA-MB231 3D spheroids were
bility wasmeasured by CellTiter-Glo assay. Inhibition of cell viability
ific siRNA and HER3-specific siRNA compared to either siRNA
eriments are shown. Differences with *P b .05, **P b .01, and ***P
s, nonsignificant).
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treated with a combination of these two siRNAs displayed a
statistically significant reduction in viability of 22% (Figure 7F).
These data suggest that pharmacological inhibition of Axl may not
be an effective single-agent therapy in Axl-expressing tumors, whereas
the simultaneous blockade of Axl and HER2/3 complexes at the cell
surface using lapatinib might be a suitable approach to optimize the
antitumor action of inhibitors targeting the Axl RTK.
Discussion
The benefits of single-target therapies are limited due to resistance
formation by the activation of alternative RTKs [38]. Understanding
the reasons for the acquired resistance would be an important key to a
more successful cancer therapy. Hence, we asked whether targeted Axl
therapies would also result in the activation of alternative RTKs. In this
study, we show for the first time, that on knockdown of Axl expression
by siRNA or pharmacological inhibition with BMS777607 and R428,
MDA-MB231 and Ovcar8 cells are able to compensate the loss of Axl
activity by the induction of HER3 phosphorylation.
Furthermore, the analysis of 20 Axl-expressing cell lines from brain,
breast, ovary, cervix, lung, and pancreatic cancer provided the first
evidence for a positive correlation between a low basal phosphorylation
of AKT S473 and the induction of HER3 activation on Axl inhibition
by BMS777607 or Axl-specific siRNA-mediated knockdown. Accord-
ingly, 7 of 10 cell lines with low pAKT S473 basal levels activated
pHER3 Y1289 on treatment with BMS777607 or Axl-specific siRNA-
mediated knockdown. In contrast, only 2 of 10 cell lines with high
pAKT S473 basal levels showed phosphorylation of HER3 Y1289 on
Axl inhibition or knockdown (Figure 3C). The high basal phosphor-
ylation of AKT S473 mainly appears in cell lines with loss of PTEN- or
PI3K-activating mutations such as the brain tumor cell lines U373,
SF126, and U118 [39,40]. These cell lines are less sensitive to the Axl/
PI3K/AKT signaling pathway inhibition and do not respond through
HER3 up-regulation to the inhibition of the upstream RTK Axl. We
conclude that inhibition of Axl induces the phosphorylation of HER3,
and this induction is not confined to a particular type of tumor but is
restricted to tumors with low basal activation of AKT.We suppose that
AKT phosphorylation is the key sensor for upstream signaling
pathways. Thus, we reason that high AKT phosphorylation levels,
resulting from PTEN loss, PI3K activating mutations, or manifold
affecting upstream pathways (RTKs, G-protein coupled receptors
(GPCRs), integrins, and cytosolic kinases), reduce the sensitivity of the
AKT sensor to upstream RTK inhibition. Vice versa, low basal AKT
phosphorylation levels indicate a higher sensitivity of the AKT sensor to
upstream RTK inhibition. Axl was shown to influence AKT
phosphorylation significantly as reviewed by Verma et al., 2011 and
Pazzez et al., 2014 [7,41]. In the case of Axl-overexpressing cells, as used
in the present study, this correlates with higher dependency on the
upstream Axl-RTK signaling pathway.
Consequently, we assume that the levels of pAKT S473 and pHER3
could be suitable biomarkers for Axl therapy response, indicating
potential clinical use. The induction of HER3 phosphorylation could
be used to discriminate between responder versus nonresponder patient
cohorts as a pharmacodynamic biomarkermonitoring therapy response.
Additionally, our results indicate that patient cohorts with expression of
Axl and low basal activity of AKT might benefit from a treatment with
Axl inhibitors due to high dependency on the Axl/PI3K/AKT signaling
pathway. To our knowledge, this is the first description of an
independent biomarker for Axl treatment regimens.A comparison of BMS777607 with R428 and with an Axl
inhibitor discovered by our group, namely, MPCD84111, indicates
that only MPCD84111 was able to block the HER3 phosphorylation
feedback loop efficiently (Figure 1B). As a common characteristic, all
three inhibitors efficiently block AKT phosphorylation. AKT has
been shown to phosphorylate the FoxO family of transcription factors
and thereby prevents their function [32]. Thus, we assume that AKT
regulates the expression of HER3 by inhibiting FoxO-dependent
transcription downstream of the Axl RTK. These results would be in
line with observations of Chandarlapaty et al., 2011 and Chakrabarty
et al., 2012 using AKT or PI3K inhibitors to induce expression of
HER3 in various tumor cell lines [30,31].
Our experiments with BMS777607 and MPCD84111 revealed
that only MPCD84111 was able to block phosphorylation of HER3
completely, although the transcriptional feedback loop was induced
in a similar extent to BMS777607 treatment (Figure 1B). As it is
widely accepted that HER3 has an impaired kinase activity, activation
of the HER3 RTK occurs only after its dimerization with other RTKs
such as HER2 or EGFR [33,28]. On the basis of the knowledge that
MPCD84111 targets HER2 (Figure 1D), a potential dimerization
partner for HER3, we focused primarily on the HER family of RTKs.
Although MDA-MB231 cells display a prototype of triple-negative
breast cancer cell lines, characterized by a low HER2 expression, our
study provides a line of arguments that HER2 is the essential
dimerization partner for HER3. The inhibition of HER2/3
heterocomplexes has been demonstrated in two independent ways.
First, in contrast to BMS777607 [24], MPCD84111 potentially
inhibits HER2, as demonstrated by kinase selectivity profiling
(Figure 1D). The HER2 inhibition capability of MPCD84111 was
also proven in HER2-expressing MCF7 breast cancer cells
(Figure 5A). Second, our results clearly demonstrate that Herceptin
as well as lapatinib, two U.S. Food and Drug Administration-
approved therapeutics for treatment of HER2-amplified breast
cancer, are able to inhibit phosphorylation of HER3 (Figure 5B).
Particularly, the inhibition of HER3 phosphorylation by Herceptin, a
humanized IgG1 monoclonal antibody raised against HER2, is worth
to be emphasized. For the sake of completeness, it is essential to
mention that Herceptin- as well as HER2-specific knockdown could
not prohibit HER3 phosphorylation totally. The complete inhibition
of HER3 phosphorylation, comparable to HER3-specific knock-
down, was only achieved by lapatinib, a dual-specific EGFR/HER2
TKI [42], or a combination of EGFR and HER2-specific siRNA.
Therefore, we cannot exclude a partial impact of EGFR in the
maintenance of HER3 phosphorylation in MDA-MB231 cells.
However, EGFR-specific knockdown as well as EGFR inhibition by
Erbitux and erlotinib (data not shown for erlotinib) did not interfere
with HER3 phosphorylation in MDA-MB231 cells. Consequently,
the dual-specific EGFR/HER2 TKI lapatinib emerged as the most
efficient strategy to prohibit HER3 phosphorylation.
To our knowledge, this is the first study that supports the
significant role of HER2 in maintaining the phosphorylation of
HER3 in MDA-MB231 cells although its quantities are hardly
detectable with the common immunoprecipitation or Western blot
analysis techniques (Figure 5, C–E).
We could also support our hypothesis of the NRG1/HER2/HER3
compensation mechanism by rescue experiments in combination
with cell viability assays in MDA-MB231 cells. Addition of the
HER3 ligand NRG1 completely compensated the inhibitory effect of
BMS777607 on cell viability, whereas proliferation was not
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implicate that up-regulation of HER3 expression by inhibition of the
Axl/PI3K/AKT pathway is a prerequisite for NRG1 ligand–
dependent activation of HER3 that might be important in the
context of the tumor microenvironment and paracrine resistance to
TKIs. The paracrine resistance is a common mechanism and has been
described recently in patients with chronic myeloid leukemia treated
with BCR-ABL kinase inhibitors as well as in patients with non–small
cell lung cancer treated with EGFR inhibitors [43]. Wang et al., 2009
reported that hepatocyte growth factor (HGF) released by stromal
fibroblasts induced resistance to EGFR inhibitors in non–small cell
lung cancer due to Met activation [44]. A tumor-supportive role for
macrophages was described by Vlaicu et al., 2013, where tumor-
associated macrophages supply tumor cells with EGFR ligands [45].
The expression and secretion of NRG1 has been demonstrated for
various components of the tumor environment, namely, fibroblasts,
endothelial cells, and peripheral monocytes, additionally supporting
the role of NRG1 in a paracrine tumor microenvironment–driven
resistance mechanism in vivo. The expression of NRG1 in fibroblasts
has been described by Wen et al., 1992 and Nagata et al., 2006
[46,47]. Cote et al., 2005 and Hedhi et al., 2011 nicely described the
paracrine function of NRG1 produced by endothelial cells on cardiac
myocytes [48,49]. Another in vivo study focused on mesenchyme-
derived NRG1 regulating the epithelial morphogenesis of mouse
embryonic submandibular glands [50]. The activation of human
monocyticlike THP-1 [THP1] (ATCCR TIB-202™) cells and
peripheral blood monocytes was companied by up-regulation and
secretion of NRG1, leading to paracrine activation of the erb
receptors and contribution to the epithelial and connective tissue
proliferation [51]. The paracrine NRG1/HER3 signal initiated by
bone marrow–derived mesenchymal stem cells and tumor-associated
mesenchymal cells was shown to promote colorectal cancer cell
progression and high NRG1 expression and was associated with poor
prognosis as shown by De Boeck et al., 2013 [52]. Additionally,
human blood serum contains considerable amounts of NRG1 in
nanogram-per-milliliter concentration range [53]. Lately, NRG1
produced by breast tumor–initiating cells was shown to promote their
proliferation and self-renewal in HER2 low-expressing tumors,
including triple-negative breast tumors [54]. Our results indicate
that MDA-MB231 cells secret NRG1 in autocrine manner and that
HER3 phosphorylation strongly correlates with the consumption of
NRG1 after Axl inhibitor treatment (Figure 4D). In vivo, an
additionally paracrine mechanism of tumor microenvironment–
driven resistance might be considered for the NRG1 and HER3;
however, this needs further investigation. The compensatory up-
regulation of HER3 expression and the maintenance of HER3
phosphorylation on inhibition of Axl suggested that a combined
inhibition of Axl and HER3 would synergistically inhibit tumor cell
viability. Cell viability was significantly reduced by a combination of
1 μM BMS777607 and 5 μM lapatinib compared to single-inhibitor
treatments (Figure 7, A and E). The efficacy of combined therapies
targeting Axl and HER2/3 was underlined by siRNA-mediated
knockdown of Axl and HER3 (Figure 7F). Analogous to the
pharmacological intervention, we achieved a significant synergistic
inhibition of cell viability by a combined application of both siRNAs.
Together, these data suggest that, although pharmacological
inhibition of Axl may not be an effective single-agent therapy in
Axl-expressing cells with low basal AKT levels, blockade of HER2/3
complexes using lapatinib might be an effective approach to block theHER3-activating feedback loop induced by Axl TKI treatment. We
assume that a monotherapy with Axl inhibitors might have limited
clinical activity due to a HER3 bypass mechanism. In cells that exhibit
low expression of HER2/3, up-regulation and phosphorylation
of HER3 are relevant mechanisms to counteract inhibition of the
Axl/PI3K/AKT pathway. Consequently, Axl inhibitors should be used
in combination with HER2/3 antagonists in Axl-positive tumors with
low basal AKT phosphorylation or with an autocrine NRG1 loop.
Therefore, alternatively to BMS777607 or R428, using MPCD84111
as an Axl inhibitor, with the capacity to block the HER2/3 bypass
mechanism by direct inhibition of HER2, would be beneficial for
cancer treatment. The final decision about using an Axl/HER2-
selective compound, e.g., MPCD84111 or an alternative strategy of
Axl inhibitors in combination with HER2/3 antagonistic agents, will of
course require additional investigation in preclinical and clinical trials.
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